What are the side effects of Flecainide (Anti-arrhythmic medication)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Flecainide can cause several side effects, including ventricular tachycardia, congestive heart failure, and enhanced AV nodal conduction, and should be used with caution in patients with structural heart disease. The most common side effects of flecainide include:

  • Dizziness
  • Visual disturbances like blurred vision or seeing spots
  • Headache
  • Nausea
  • Fatigue
  • Tremors Some patients may experience more serious side effects, such as:
  • New or worsening heart rhythm problems
  • Signs of heart failure, including swelling in ankles/feet, unusual tiredness, and shortness of breath
  • Fainting or severe dizziness Flecainide can also cause a dangerous condition called proarrhythmia, where it paradoxically worsens heart rhythm problems, particularly in patients with structural heart disease 1. This medication may interact with many other drugs, so it's essential to inform your doctor about all medications you're taking. Regular monitoring with ECGs and blood tests is typically required while on flecainide 1. The side effects occur because flecainide works by slowing electrical conduction in the heart, which can affect other electrically active tissues in the body like the brain and nervous system. If you experience concerning side effects while taking flecainide, contact your healthcare provider immediately rather than stopping the medication abruptly.

It's also important to note that flecainide should be used with caution in patients with certain conditions, such as:

  • Structural heart disease, including ischemic heart disease
  • Atrial flutter with 1:1 AV conduction
  • QT prolongation
  • Torsades de pointes
  • Worsening heart failure
  • Bradycardia
  • Sinus or AV conduction disease
  • Cardiogenic shock
  • Brugada syndrome
  • Renal dysfunction
  • Hepatic dysfunction
  • QT-prolonging drugs
  • Amiodarone, digoxin, ritonavir, saquinavir, tipranavir 1.

Overall, flecainide can be an effective medication for treating certain heart rhythm disorders, but it's essential to carefully weigh the potential benefits and risks and to closely monitor patients for any signs of adverse effects.

From the FDA Drug Label

In patients treated with flecainide for sustained VT, 80% (51/64) of proarrhythmic events occurred within 14 days of the onset of therapy. New or worsened CHF occurred in 6.3% of 1046 patients with PVCs, non-sustained or sustained VT. Of 297 patients with sustained VT, 9.1% experienced new or worsened CHF. New or worsened CHF was reported in 0. 4% of 225 patients with supraventricular arrhythmias. There have also been instances of second- (0.5%) or third-degree (0.4%) AV block. Patients have developed sinus bradycardia, sinus pause, or sinus arrest, about 1. 2% altogether. The frequency of most of these serious adverse events probably increases with higher trough plasma levels, especially when these trough levels exceed 1 mcg/mL. Table 1: Most Common Non-Cardiac Effects in Ventricular Arrhythmia Patients Treated with Flecainide in the Multicenter Study

  • Dizziness includes reports of dizziness, lightheadedness, faintness, unsteadiness, near syncope, etc. † Visual disturbance includes reports of blurred vision, difficulty in focusing, spots before eyes, etc Adverse Effect Incidence All 429 Patients at Any Dose Incidence by Dose During Upward Titration 200 mg/Day (N=426) 300 mg/Day (N=293) 400 mg/Day (N=100) Dizziness* 18.9% 11.0% 10.6% 13.0% Visual Disturbances† 15.9% 5.4% 12.3% 18.0% Dyspnea 10.3% 5.2% 7.5% 4.0% Headache 9.6% 4.5% 6.1% 9.0% Nausea 8.9% 4.9% 4.8% 6.0% Fatigue 7.7% 4.5% 4.4% 3.0% Palpitation 6.1% 3.5% 2.4% 7.0% Chest Pain 5.4% 3.1% 3. 8% 1.0% Asthenia 4.9% 2.6% 2.0% 4.0% Tremor 4.7% 2.4% 3.4% 2.0% Constipation 4.4% 2.8% 2.1% 1.0% Edema 3.5% 1.9% 1.4% 2.0% Abdominal Pain 3.3% 1.9% 2.4% 1. 0%

The side effects of Flecainide include:

  • Proarrhythmic events: 13% incidence in patients with sustained VT, with 80% of events occurring within 14 days of therapy initiation 2
  • Cardiac effects: new or worsened CHF (6.3% of patients with PVCs, non-sustained or sustained VT), second- or third-degree AV block (0.5% and 0.4%, respectively), sinus bradycardia, sinus pause, or sinus arrest (1.2% altogether) 2
  • Non-cardiac effects:
    • Neurological: dizziness (18.9%), visual disturbances (15.9%), headache (9.6%), fatigue (7.7%), tremor (4.7%) 2
    • Gastrointestinal: nausea (8.9%), constipation (4.4%), abdominal pain (3.3%) 2
    • Respiratory: dyspnea (10.3%), chest pain (5.4%) 2
    • Other: palpitation (6.1%), asthenia (4.9%), edema (3.5%) 2

From the Research

Side Effects of Flecainide

The side effects of flecainide can be categorized into several groups, including:

  • Extracardiac adverse effects, such as dizziness, visual disturbances, headache, nausea, dyspnea, and chest pain, which were reported in a study published in The American Journal of Cardiology in 1984 3
  • Cardiac side effects, including ventricular tachyarrhythmias, severe bradycardia, and cardiogenic shock, which can be life-threatening, as reported in a case study published in The Journal of Emergency Medicine in 2020 4
  • Electrocardiographic changes, such as prolongation of the PR and QRS intervals, which can indicate toxicity, as reported in a study published in Annals of Internal Medicine in 1987 5

Common Side Effects

The most frequently reported side effects of flecainide include:

  • Dizziness (30%) and visual disturbances (28%), which often occur together 3
  • Headache, nausea, dyspnea, and chest pain, which occur at incidences of 6 to 9% 3
  • Other adverse experiences, which occur at incidences of greater than or equal to 5% 3

Serious Side Effects

Flecainide can cause serious side effects, including:

  • Cardiac arrest, dysrhythmias, and heart failure, as reported in a case study published in The Journal of Emergency Medicine in 2020 4
  • Ventricular tachyarrhythmias and severe bradycardia, which can be life-threatening, as reported in a study published in Annals of Internal Medicine in 1987 5
  • Acute kidney injury (AKI) resulting in flecainide accumulation, which can be high risk for missed diagnosis in the emergency department, as reported in a case study published in The Journal of Emergency Medicine in 2020 4

Special Considerations

Flecainide should be used with caution in patients with certain medical conditions, such as:

  • Structural heart disease, as reported in a study published in The American Journal of Cardiology in 2020 6
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC), as reported in a study published in Europace in 2022 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Extracardiac adverse effects of flecainide.

The American journal of cardiology, 1984

Research

The Case of Flecainide Toxicity: What to Look for and How to Treat.

The Journal of emergency medicine, 2020

Research

Use of Flecainide for the Treatment of Atrial Fibrillation.

The American journal of cardiology, 2020

Research

Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.